Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma
Theranostics · 01.01.2026 · 16 (6) · 2748-2763
DOI: 10.7150/thno.126920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 01.01.2026. Verfasst von Behnaz Ghaemi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, 20892, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Positron-Emission Tomography, Single-Domain Antibodies, B-Cell Maturation Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Multiple myeloma (MM) is an incurable plasma cell malignancy with limited disease-specific imaging options. Current diagnostic methods often fail to detect early disease states and minimal residual disease, highlighting the need for more precise molecular imaging and targeted therapeutic approaches. We developed a radiolabeled nanobody targeting B-cell maturation antigen (BCMA) to enable both high-contrast molecular imaging and targeted radioligand therapy in human MM models.
Methods
A high-affinity anti-BCMA nanobody was labeled with [18F]FPy-pyridine prosthetic group for PET imaging and [131I]I for radioligand therapy. Target expression and in vitro binding affinity and specificity were assessed using biolayer interferometry, flow cytometry, and cell-based assays. PET imaging studies were performed in subcutaneous MC38-human BCMA xenografts and systemic human MM models (H929 and RPMI8226 cell lines) administered intravenously in NSG mice. Therapeutic efficacy was evaluated using a fractionated treatment regimen with [131I]I-BCMA-Nb (four weekly injections of 7.4 or 18.5 MBq), monitoring tumor burden via bioluminescence imaging and [18F]FDG-PET. Toxicity assessment included body weight monitoring, complete blood counts, biochemical analyses, and histopathological examination. Results: [18F]FPy-BCMA-Nb demonstrated high binding affinity and excellent tumor specificity with rapid systemic clearance. PET imaging showed significantly higher uptake in BCMA-positive lesions (6-8% ID/g) compared to controls (1% ID/g), with minimal kidney retention (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, 20892, USA.
- Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, NIH, Rockville, Maryland, 20850, USA.
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, 20892, USA.
- Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, Department of Medicine, Myeloma Division University of Miami, Florida, 33146, USA.
Zitieren
APA
Ghaemi, B., Olkowski, C. P., Basuli, F., Shi, J., Young, R., Kazandjian, D., Landgren, O., Hill, E., Choyke, P. L., & Jacobson, O. (2026). Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. Theranostics, 16(6), 2748-2763. https://doi.org/10.7150/thno.126920
Vancouver
Ghaemi B, Olkowski CP, Basuli F, Shi J, Young R, Kazandjian D, et al. Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. Theranostics. 2026;16(6):2748-2763. doi:10.7150/thno.126920
BibTeX
@article{Ghaemi2026,
author = {Ghaemi, Behnaz and Olkowski, Colleen P and Basuli, Falguni and Shi, Jianfeng and Young, Ryan and Kazandjian, Dickran and Landgren, Ola and Hill, Elizabeth and Choyke, Peter L and Jacobson, Orit},
title = {Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma},
journal = {Theranostics},
year = {2026},
volume = {16},
number = {6},
pages = {2748--2763},
doi = {10.7150/thno.126920}
}
EUVIMED